PDCD1 and skin squamous cell carcinoma: Hanna et al. analyzed 55 cSCC patients and reported that higher TMB (median: 25 vs. 11 mut/Mb) was associated with positive response to treatment with a PD-1 inhibitor (cemiplimab, pembrolizumab, or nivolumab) [21].